Alpha-beta (αβ) T cells, gamma-delta (γδ) T cells and natural killer (NK) cells are three different kinds of lymphocytes, and clinics in Japan often culture one or more of them for immune cell therapy. Gamma-delta T cells usually make up only 1–10% of the T cells in adult blood, with most of the rest being alpha-beta T cells; NK cells account for about 5–20% of circulating lymphocytes. In Japan, expanding a patient's own, unmodified immune cells and infusing them back is generally regulated as Class III under the Act on the Safety of Regenerative Medicine.

The three cell types at a glance

Alpha-beta T cells Gamma-delta T cells NK cells
Immune branch Adaptive T cells with innate-like features Innate
Share of blood cells Most T cells About 1–10% of T cells, varies widely About 5–20% of lymphocytes
How they recognize targets T cell receptor reads peptides presented on MHC (HLA) molecules Generally independent of antigen processing and MHC restriction Balance of activating and inhibitory signals; spot cells that have lost MHC class I
Common lab stimulus for expansion Anti-CD3 antibody plus IL-2 Zoledronate plus IL-2 Cytokine combinations or feeder cells

Alpha-beta T cells: the majority

Every T cell carries a T cell receptor made of two protein chains. In most T cells those chains are alpha and beta. The helper and cytotoxic T cells you may have read about in a lab report are, for the most part, alpha-beta T cells.

Colorful illustrated spiked and oblong microbe-like shapes arranged around a syringe on a light blue textured background.

Alpha-beta T cells are precise. Each one recognizes a specific peptide only when it is displayed by an MHC molecule (called HLA in humans) on the surface of another cell. That precision gives the adaptive immune system its memory. It also has a weak spot: a tumor cell that reduces its MHC expression becomes harder for these cells to see.

How labs expand them. The usual approach stimulates lymphocytes with an antibody against CD3, part of the T cell receptor complex, together with the growth factor interleukin-2 (IL-2). A Japanese randomized trial published in The Lancet in 2000 used exactly this method: patients' own lymphocytes were activated in vitro with recombinant IL-2 and anti-CD3 antibody and then returned to patients after liver cancer surgery. Clinic materials in Japan often describe this kind of treatment as "activated autologous lymphocyte therapy."

Gamma-delta T cells: a small population with a different rulebook

A minority of T cells use gamma and delta chains instead. A 2020 review in Cellular & Molecular Immunology reports that gamma-delta T cells usually make up between 1% and 10% of CD3-positive T cells in human blood, with large differences between individuals. One subset, Vγ9Vδ2, accounts for anywhere from 50% to more than 95% of the gamma-delta T cells in blood.

What makes these cells interesting is how they recognize targets. According to the same review, gamma-delta T cells typically recognize their ligands without antigen processing and without MHC restriction. The main Vδ2 subset responds to small molecules called phosphoantigens, and that response depends on a surface molecule called BTN3A1. Because they are not tied to MHC, gamma-delta T cells are often described as sitting between innate and adaptive immunity.

How labs expand them. Labs exploit that phosphoantigen pathway with zoledronate, a bisphosphonate drug better known for treating bone conditions. A Japanese study published in Cytotherapy in 2008 cultured blood cells with zoledronate (5 μM) and IL-2 (1,000 IU/mL) for 14 days and obtained more than 1 billion gamma-delta T cells from 45–70 mL of peripheral blood.

NK cells: no prior introduction needed

NK cells are not T cells. They have no T cell receptor and belong to the innate immune system. A 2018 review in Frontiers in Immunology states that NK cells represent 5–20% of circulating lymphocytes in humans.

A person in a light protective coat holds a syringe above a small glass container.

NK cells weigh activating and inhibitory signals from a target cell. A central rule is "missing self": healthy cells display MHC class I molecules, which tell NK cells to stand down. Some virus-infected or cancerous cells reduce those molecules to hide from T cells, and that makes them more visible to NK cells. NK cells then kill the target by releasing perforin and granzyme B. In that sense, NK cells and alpha-beta T cells cover each other's blind spots. For more on what NK cells do and how clinics use them, see our NK cell therapy guide.

How labs expand them. Traditional NK expansion often relies on feeder cells, frequently derived from cancer cell lines, that are co-cultured with NK cells to stimulate growth. A 2025 review in Frontiers in Immunology notes safety and quality concerns with feeder cells and describes feeder-free alternatives, including cytokine combinations, antibody stimulation and blood components. Each processing facility chooses its own method.

What "combined" immune cell therapy means

Some Japanese clinics offer what they call combined or composite immune cell therapy. It is not a new cell type. It means several cell types, for example alpha-beta T, gamma-delta T and NK cells, are cultured together or separately and infused together. The mix, the proportions and the culture method vary between providers, so the same name can describe different protocols. Reasonable questions for the doctor:

  1. Roughly what share of the final product is each cell type, and how is that measured before release?
  2. Are the cells my own or from a donor? Are they genetically modified?
  3. How many days pass between the blood draw and the infusion, and how many trips to Japan does that mean?

How Japan classifies these treatments

Japan's Ministry of Health, Labour and Welfare (MHLW) issued an enforcement notice on 15 May 2025 that addresses the Class II criterion of using cultured cells "to rebuild, repair or form" body structure or function. The notice gives lymphocyte activation therapy for treating malignant tumors as an example that does not fall under that criterion. As a result, therapy using a patient's own, non-genetically-modified immune cells is generally Class III.

The MHLW's consolidated Q&A of 18 February 2025 adds that cultured lymphocytes given under the skin or into the abdominal cavity for cancer immunotherapy count as the same use and remain Class III. Cells that have been genetically modified, or cells from another person (allogeneic cells), are Class I, the highest-risk class, which carries a 90-day waiting period after the plan is filed.

Situation Typical class
Patient's own cells, expanded, no genetic modification Class III
Donor (allogeneic) cells Class I
Genetically modified cells, such as CAR-T made outside an approved product Class I

Whatever the class, the clinic must have its plan reviewed by a certified committee and filed before offering the treatment, and most of these treatments are self-pay (jiyū shinryō), outside public health insurance. Approved CAR-T products follow a separate pharmaceutical approval path; our immunotherapy in Japan article explains the difference, and Japan's Act on the Safety of Regenerative Medicine covers the three classes in full.

On the evidence, the National Cancer Center Japan's Cancer Information Service states that immunotherapy offered as self-pay treatment has not been proven effective and is not established medical care. If you are weighing one of these treatments, the doctor in Japan can walk you through the available study data and what will be measured before and after.

Who can ask directly, and who needs a review first

  • Healthy adults interested in NK or other immune cell treatments for wellness or anti-aging can contact us directly.
  • Anyone being treated for cancer or another illness needs a Japanese doctor to review their medical records first, and should talk with their current oncologist about possible interactions with ongoing treatment such as chemotherapy or checkpoint inhibitors. The same applies to minors, people who are pregnant or planning pregnancy, and people with advanced cancer, serious heart or brain conditions, or psychiatric illness.

A gloved hand holds a reflective slide above another slide, with a small purple-capped tube in the foreground.

If a clinic's description and its stated class don't line up, send the clinic's name and the treatment description to our advisors and we will confirm whether it has filed a provision plan for that treatment. You can also start with our pre-screening form.

Frequently asked questions

What is the difference between alpha-beta and gamma-delta T cells?

The difference is in the T cell receptor chains and how the cells recognize targets. Alpha-beta T cells are the majority and read peptides presented on MHC molecules; gamma-delta T cells usually make up 1–10% of blood T cells and generally recognize targets without MHC restriction.

Are NK cells a type of T cell?

No. NK cells are innate lymphocytes with no T cell receptor. They make up about 5–20% of circulating lymphocytes and decide what to attack by balancing activating and inhibitory signals.

What is gamma-delta T cell therapy?

It is a treatment in which a patient's gamma-delta T cells are expanded in the lab, typically with zoledronate and IL-2, and infused back. In Japan, the autologous version is generally Class III under the Safety Act.

Is immune cell therapy in Japan covered by insurance?

Most clinic-based immune cell therapy is self-pay. Approved products such as CAR-T are handled under a separate approval and insurance path.

Sources: Kabelitz D et al., Cellular & Molecular Immunology 2020 (gamma-delta T cell review); Abel AM et al., Frontiers in Immunology 2018 (NK cell review); Lee J et al., Frontiers in Immunology 2025 (feeder-free NK expansion review); Takayama T et al., The Lancet 2000;356:802; Kondo M et al., Cytotherapy 2008; MHLW consolidated Q&A on the Act on the Safety of Regenerative Medicine (18 February 2025); MHLW enforcement notice of 15 May 2025; National Cancer Center Japan, Cancer Information Service, immunotherapy page. Checked November 2026; MHLW publications prevail.

Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.